WOBURN, Mass. - iSpecimen Inc. (NASDAQ:ISPC), a company that operates an online marketplace for medical research biospecimens, announced the pricing of its public offering at $3.00 per share, aiming to raise approximately $5 million. The offering includes common stock and pre-funded warrants, with the latter being offered at a slightly reduced price of $3.00 minus $0.0001 per warrant.
The funds raised from this offering are designated for several corporate purposes, including the repayment of outstanding debt, potential acquisitions, investments in new businesses, products, and technologies, and for marketing and advertising services. Any remaining funds will be allocated for working capital needs.
WestPark Capital, Inc. is serving as the exclusive placement agent for the offering, which is scheduled to close on Thursday, October 31, 2024, subject to standard closing conditions. The offering is made under the company's registration statement on Form S-1, which was filed with the U.S. Securities and Exchange Commission (SEC) on October 18, 2024, and declared effective on October 29, 2024.
Investors interested in the offering may obtain copies of the final prospectus, when available, from WestPark Capital, Inc. located in Los Angeles, CA. The final prospectus will also be accessible on the SEC's website following its filing.
iSpecimen's cloud-based platform facilitates the procurement of human biospecimens by connecting researchers with a network of healthcare providers. This network includes hospitals, labs, biobanks, blood centers, and other healthcare organizations.
The press release includes forward-looking statements that are subject to various risks and uncertainties, which could cause actual results to differ materially from those projected. The company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of their date. iSpecimen does not undertake any obligation to update or revise these statements in light of new information or future events.
This article is based on a press release statement and provides a summary of the key facts without promotion or speculation.
In other recent news, iSpecimen Inc. has regained compliance with Nasdaq's minimum bid price requirement, following a 1-for-20 reverse stock split. Alongside this, the company has faced a Demand for Arbitration from its former Chief Information Officer, Benjamin Bielak, seeking alleged unpaid bonuses and severance totaling $586,800. iSpecimen has expressed its intention to defend against these claims. Financially, the company reported a decrease in Q1 2024 revenue, falling to $2.3 million from $3 million in Q1 2023, due to a 39% decrease in specimen count. However, iSpecimen secured a $1 million loan, facilitated by Westpark Capital, Inc., and introduced new members to its board. These recent developments also include the company's relocation to a new office space in Woburn, MA. Lastly, iSpecimen has been focusing on technological advancements and improving the quality of its supplier network, establishing a pipeline of new business opportunities worth approximately $1.5 million.
InvestingPro Insights
As iSpecimen Inc. (NASDAQ:ISPC) moves forward with its public offering to raise approximately $5 million, investors should consider some key financial metrics and insights provided by InvestingPro.
According to InvestingPro data, iSpecimen's market capitalization stands at a modest $2.76 million, reflecting its current position in the biospecimen marketplace industry. The company's revenue for the last twelve months as of Q2 2023 was $10.51 million, with a revenue growth of 3.82% over the same period. Notably, the company experienced a significant quarterly revenue growth of 76.21% in Q2 2023, indicating potential market traction.
However, investors should be aware of some challenges facing the company. An InvestingPro Tip highlights that iSpecimen is "quickly burning through cash," which aligns with the company's decision to raise funds through this public offering. Additionally, the company is "not profitable over the last twelve months," with an operating income margin of -97.53% for the last twelve months as of Q2 2023.
On a positive note, another InvestingPro Tip indicates that iSpecimen "holds more cash than debt on its balance sheet," which could provide some financial flexibility. The company's price-to-book ratio of 0.45 suggests that it might be undervalued relative to its book value.
For investors considering iSpecimen's stock, it's worth noting that the company's share price has experienced significant volatility. The stock has taken a "big hit over the last week" with a 1-week price total return of -10.97% as of the latest data. The year-to-date price total return stands at -57.85%, reflecting the challenges the company has faced in 2023.
These insights from InvestingPro provide valuable context to iSpecimen's public offering and its financial position. Investors interested in a more comprehensive analysis can access additional tips and data through the InvestingPro product, which offers a total of 8 tips for iSpecimen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.